Drug class refractoriness, not number of prior lines of therapy, properly classify patients with relapsed and refractory multiple myeloma.
Luciano José Megale CostaSmith GiriSusan BalGayathri RaviKelly N GodbyPublished in: British journal of haematology (2023)